PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
Completed
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05139680
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Phase 2
Terminated
- Conditions
- Acute Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT05139615
- Locations
- 🇷🇸
Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
🇷🇸Clinical Center of Kragujevac, Kragujevac, Serbia
🇷🇸Healthcare Center Uzice, Užice, Serbia
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05132101
- Locations
- 🇰🇷
Pfizer Local Country Office, Seoul, Korea, Republic of
Korean Regulatory Post Marketing Surveillance for Somavert
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT05131100
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05129475
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Target Occupancy Study With Ritlecitinib.
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05128058
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
Phase 2
Terminated
- Conditions
- Achondroplasia
- Interventions
- Biological: Recifercept
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05116046
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸Nemours Children's Hospital, Delaware, Wilmington, Delaware, United States
🇦🇺Murdoch Children's Research Institute, Parkville, Victoria, Australia
Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium
Withdrawn
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05116267
- Locations
- 🇧🇪
Pfizer Site, Brussels, Belgium
A Study of PF-07258669 In Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT05113940
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants
Phase 1
Completed
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Drug: 450mgDrug: 150mgDrug: Placebo
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05107492
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath